HIV1--HIV2 coinfection in Mexico.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

HIV1--HIV2 coinfection in Mexico.

Int Conf AIDS. 1992 Jul 19-24;8(2):A15 (abstract no. PoA 2073). Unique Identifier : AIDSLINE ICA8/92400366
Vazquez-Valls E; Lequin RM; Campos-Lopez P; Calkhoven PG; Unidad de Investigacion Biomedica de Occidente, IMSS,; Guadalajara, Mexico.

Abstract: OBJECTIVE: To obtain evidence for HIV2 infection in Mexico. METHODS: In 1990, in a quality control evaluation, 229 (181 positive for HIV1 and 48 negative) serum samples from 4,200 sera obtained between 1985 to 1989 searching for HIV1 and HIV2 antibodies in several groups (male homosexuals and bisexuals, blood donors, prostitutes and heterosexual of both sexes), were screened with Vironostika HTLV III EIA and Vironostika HIV MIXT (HIV1 and HIV2) EIA, (Organon Teknika). Positive samples were additionally screened with LiaTek (HIV1 and HIV2) and confirmed by new LAV-Blot II (Diagnostics Pasteur) and HIV2 Western Blot (Cambridge Biotech). RESULTS: The 181 positive samples were concordantly positives in HTLV III and HIV MIXT EIA's. Only two of these samples (code #30 and #79) were positive for both HIV1 and HIV2 in LiaTek, and belonged to asymptomatic active male homosexuals that have had frequent sexual contacts with European, North American and Canadian partners. The LiaTek results for #30 (gp41:2+; p17:2+; gp36:1+) and #79 (gp41:2+; p31:1+; p24:1+; gp36:1+), were confirmed by Western Blot showing the following bands: #30: gp105: +/- (status undetermined), and #79: gp140: +/-; gp105: +; gp36: +/-; p26: +/- (status undetermined). In 1992 a Western Blot from subject #30, revealed: gp140, gp34 trimer, gp34 trans-membrane, p31 and p26 bands (positive, WHO criteria). Subject #79 was not traceable. CONCLUSION: At least one HIV1/HIV2 case was detected in our study. PCR and further epidemiological investigations are needed.

Keywords: Bisexuality Blood Donors Homosexuality Human HIV/*ISOLATION & PURIF HIV Infections/COMPLICATIONS/EPIDEMIOLOGY/*MICROBIOLOGY HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF HTLV-BLV Infections/COMPLICATIONS/EPIDEMIOLOGY/*MICROBIOLOGY Mass Screening Mexico/EPIDEMIOLOGY Prostitution Risk Factors Sex Behavior ABSTRACT
921230
M92C4981

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .